as autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP)?' that frequently afflict patients with this disease? This report will address several of these questions and review some of the recently acquired information regarding antibody expression in CLL and associated systemic autoimmune diseases. First, it is helpful to review the mechanisms that contribute to antibody diversity.
GENERATION OF ANTIBODY DIVERSITY
Ig gene rearrangement. The antibody molecule consists of two polypeptide chains that are encoded by gene complexes located on different chromosome^.^^'' During B-cell development, discontinuous elements within these gene complexes undergo a series of Ig gene rearrangements to form the exons that ultimately may encode the heavy and light chains of the antibody molec~le'~-'~ (Fig 1) . Generally, the first Ig gene rearrangements occur within the Ig heavy chain gene complex. More than two dozen minigenes, termed diversity segments (D),l6-I9 are positioned between six functional JH minigenes2'S2' and 100 to 200 heavy chain variable region genes (V, genes).22 Each VH gene belongs to one of at least 6 subgroups, with each subgroup comprised of V genes that share 280% nucleic acid sequence homology.23 Through Ig gene rearrangement, one or more D gene segments is joined with a single JH element.24s25 The resulting DJH complex may then rearrange with a VH gene17322,26,27 to form a VHDJH exon that may encode the variable portion of the antibody heavy hai in.^^,^^ After successful VHDJH rearrangement, one of approximately 70 K V genes (V, genes)28s34 rearrange to one of five J. minigenes:' thereby generating an exon that may encode a K light chain variable region.21,35,36 Should this rearrangement fail to generate a functional gene, then one of approximately 70 X light chain V genes (V, genes)37338 may rearrange to one of four functional JA-CA complexes3944 to generate an exon that may encode a X light chain variable region. The final products of such genetic gymnastics are the somatically generated genes that encode the two polypeptide chains of the antibody molecule.
After successful Ig gene rearrangement, a highly specialized process may introduce numerous mutations in the rearranged and expressed Ig V genes4548 (Fig 1) . This process, called somatic hypermutation, is not triggered by the mere expression of Ig genes or B-cell p r o l i f e r a t i~n .~~~~~ Rather, somatic hypermutation apparently operates only in a subset of B lymphocytes at discrete times during an immune response to antigen.48*5'v5Z Stru ctural analyses of the antibodies produced at different times in an immune response show that, at 6 to 14 days after antigenic stimulation, the Ig V genes expressed by antigen-reactive B cells may accumulate somatic mutations at rates nearly a thousand times higher than that of normal (eg, I 10-3/base pair/cell division).45,46,53-56 Thereafter, the mutation rates diminish as the B cells differentiate into memory or plasma ~e l l s . '~-~~ Selection for B cells expressing antibodies of higher affinity for antigen enhances the cumulative number of nonconservative mutations at sites that encode parts of the antibody that bind to antigen.47,52@64 Through this process, high-affinity antibodies can be generated against almost any antigen, including self antigen^.^^^^' As a consequence, B cells are always capable of making potentially pathogenic highaffinity autoantibodies and self tolerance is never assured. Thus, immunoregulatory mechanisms must perpetually o p erate to prevent production of pathogenic autoantibodies. Ig variable region structure. Comparison of the amino acid sequences from different antibody variable regions shows three discrete segments of extreme hypervariabilit~.~~ Affinity labeling and crystallographic studies substantiated earlier contentions that the hypervariable regions on both chains fold together to form the antigen-combining site.66-70 Hence, these regions of hypervariability are designated the complementarity-determining regions (CDRs). The third CDR is generated through the recombinatorial process joining the antibody light chain V gene with the J segment, in the case of the light chain, or the VH gene with the somatically generated DJH segment of the antibody heavy hai in.'^,'^,'^,^^,^ ' The diversity in first and second hypervariable regions reflects, in part, differences between each of the various inherited antibody V genes.22,26,34,72-78 As discussed above, somatic hypermutation subsequent to antibody V gene rearrangement may also play an important role in increasing the amino acid sequence diversity noted within these regions.
Together, the CDRs of both the antibody heavy and light chains fashion the specificity of the Ig molecule. Owing to the need for antibodies to bind a diverse array of different pathogens, there exists great potential for diversity in the tertiary structures of these regions. This potential is reflected by the fact that the combining site of each antibody may possess determinants of unique specificity that, in turn, may be recognized by anti-idiotypic antibodies.
AUTOANTIBODY-ASSOCIATED CROSS-REACTIVE IDIOTYPES IN CLL
Despite the tremendous potential for diversity, the antibodies produced by leukemia B cells of unrelated CLL patients often share common idiotypic determinants. Initially identified using highly absorbed heterologous antisera,79 and then more recently using murine M O A~S ,~~'~ these common idiotopes, designated cross-reactive idiotypes (CRIs), were defined initially on IgM autoantibodies such as RFs. In an early study of more than 30 CLL patients, 5 of 20 (25%) with K light chain-expressing CLL had malignant cells that expressed a CRI defined by 17.109, a mouse MoAb raised against an IgM RF Furthermore, approximately 20% of both K and X light-chain-expressing CLL were found to react with G6,85,86 an MoAb specific for an Ig heavychain-associated CRI present on several RF paraproteins." Yet, an additional MoAb specific for a distinct RF heavychain-associated CRI, named Lc I ,86*88 labeled neoplastic Igexpressing B cells from 7 of 56 (1 3%) patients with CLL and related B-cell lymphomas.86 Another 2 cases (4%) in this study were found to have malignant cells reactive with B6, a third MoAb specific for an autoantibody heavy-chain-associated CRI that is distinct from either the G6-CRI or L c I -C R I .~~,~~ More recently, additional autoantibody-associated CRIs have also been found to be expressed frequently in CLL and related B-cell neoplasms.w391
Molecular characterization of several such CRIs shows that each may reflect expression of a conserved Ig V gene with little or no somatic mutation. For example, 17.109-reactive leukemia cells from unrelated CLL patients express Ig V, genes that are highly homologous with a conserved germline V,3 gene designated H~m k v 3 2 5 .~~ This highly conserved Ig V, gene is but 1 of 70 Ig V, genes found present in the human haploid genome. Similarly, nucleic acid sequence analyses of the Ig heavy chain genes expressed by G6-reactive leukemic cells of unrelated CLL patients shows that each is homologous to a VH1 gene frequently used by human fetal splenocytes designated 5 lpl .93,94 5 l p l is but one of an estimated 20 to 60 VH genes that comprise the v H 1 gene subgroup.22 However, despite expressing homologous VH l genes, G6-reactive leukemic cells have been found to use JH3, JH4, J H~, or JH6
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From gene segments and markedly different D segments. Furthermore, comparisons of G6-reactive and G6-negative antibody heavy chains indicate that the G6-CRI may be relatively resilient to substitutions within CDR3, but affected by differences in CDRl and CDR2 that are found encoded by other VH genes of the v H 1 subgroup. As such, the G6-CRI in CLL is an excellent marker for expression of 51pl with little or no somatic mutation. Accordingly, the frequent expression of such CRIs in CLL implies that the leukemia B cells in this disease express a highly restricted repertoire of Ig V genes that have not diversified significantly from the germline DNA.
lg GENE REARRANGEMENT IN CLL
Analyses of CLL B cells not selected for expression of antibodies with particular binding specificities or CRIs show a generalized bias in the rearrangement and expression of select Ig V genes. Several investigators have noted that the Ig VH genes of the relatively small VH subgroups, vH4 and VH5, and the single copy vH6 gene are rearranged in CLL at frequencies that are disproportionate to the relative sizes of these subgroups in the germline DNA.5,95-97 On the other hand, the largest VH gene subgroup, the vH3 gene family, seems underrepresented among the VH gene used in CLL. [96] [97] [98] Furthermore, within an Ig VH gene subgroup there may exist a bias toward the rearrangement of certain individual VH genes. As discussed, this may be exemplified by the G6-encoding gene 5 1 p I, a member of the relatively large VH 1 gene s~b g r o u p .~~,~~ Deane and Norton99 noted that 3 of the 9 Ig VH1 gene rearrangements they identified in CLL were homologous to 51pl. In contrast, these investigators did not find this gene used in a set of 9 VH1 gene rearrangements detected among pre-B acute lymphocytic leukemias, suggesting that the biased rearrangement of 5 l p 1 is peculiar to CLL. In another survey of 44 patients with CLL, two-thirds (10 of 15) of the 15 leukemia samples found to have functionally rearranged VH 1 genes were found to use VH 1 genes homologous to 5 1 p 1 .loo Two of the 15 ( 13%) were homologous to V35. This v H 1 gene is distinctive in that it is the closest VH1 gene to the D and J H gene complexes."' As 5 l p l apparently is rearranged and expressed more often than V35, proximity to the D and J H loci evidently does not determine the hierarchy at which v H 1 genes are expressed in CLL. Finally, because 5 lpl is but only 1 of approximately 20 to 60 VH 1 genes in the Ig heavy chain gene these data indicate that VH1 gene rearrangement in CLL is not random.
At least two mechanisms may contribute to the frequent rearrangement and expression of certain Ig V genes in CLL. First, certain Ig V genes may undergo Ig gene rearrangement more frequently than other Ig V genes, possibly due to intemal or neighboring recognition sequences for enzymes involved in Ig gene rearrangement."' On the other hand, certain Ig V genes may encode antibodies that have peculiar binding specificities that are selected during leukemogenesis, resulting in a biased repertoire of Ig V genes used in CLL. These mechanisms need not be mutually exclusive.
To determine whether nonrandom Ig gene rearrangement occurs in CLL independent of selection for expressed Ig protein, we examined the abortive V, gene rearrangements in X light chain expressing CLL (X-CLL).Io3 Although most of these X-CLL had rearranged both K light chain alleles, 9 had rearranged only one, providing us with a total of 57 identified K light chain gene rearrangements in a sample group of 33 A-CLL. We found the V, gene encoding the 17.109-CRI, Humkv325, to be involved in 8 of these nonproductive rearrangements. Another conserved V,3 gene, designated Vg, was rearranged nonproductively in 3 of the A-CLL. Similar to Humkv325, this Studies on the Ig V genes used by leukemia B cells have shown that the process of somatic hypermutation is not active in CLL. First, the Ig V genes expressed in any given CLL Bcell clone are homogeneous, or without significant "intraclonal d i~e r s i t y . "~* ,~~, ' O~'~~ This contrasts with non-Hodgkin's lymphomas (NHL) of follicular center cell origin. Analyses of these lymphomas show substantial intraclonal diversity in the expressed Ig variable regions suggestive of ongoing somatic hypermutation.'" Furthermore, the Ig V genes expressed in most CLL share extensive homology (>97%) with known germline Ig V genes.89~92~93~97~99.100,106,Lo9~110 Collectively, these studies indicate that CLL may express germline Ig V genes with little or no somatic mutation.
However, there are some exceptions to this generalization. Humphries et a195 noted that the leukemia cells from related CLL patients expressed extensively mutated Ig VH genes belonging to the relatively small VH5 subgroup. In addition, they noted that 30% of the CLL patients in their survey had leukemia cells that had rearranged one Ig vH5 gene, designated VH25 1. These investigators also examined Ig VHS geneexpressing CLL B-cell populations from 11 different patients."' Because prior studies indicated that Ig VH genes of this small subgroup are highly conserved and nonpolymorphic,"' they compared the primary nucleic acid sequences of the expressed VH genes with that of known VH5 genes. In 9 of the 11 CLL, they found the nucleic acid sequences of the expressed Ig VH25 1 genes to differ substantially (594% homology) from that of the known germline sequence. Importantly, the nucleic acid base differences resulted in amino acid substitutions were clustered primarily within the CDRs, regions that form the pocket of the antibody's antigencombining site. As discussed, such substitutions often are For personal use only. on August 30, 2017. by guest www.bloodjournal.org From noted in the Ig selected in an antigen-driven secondary immune response. Accordingly, it appears that these CLL express antibodies that had been selected for their ability to bind some unknown antigen(s).
Expression of mutated Ig VH genes by these CLL may reflect a unique property of the Ig VH25 1 gene. This Ig vH5 gene, for example, is distinctive in that it drives relatively high rates of transcription in the germline nonrearranged configuration.' l 3
To evaluate whether the Ig vH5 genes in CLL are distinctive, we recently examined for vH5 Ig gene rearrangements in leukemia cells from 68 patients that satisfied clinical and diagnostic criteria for common B-cell CLL. 'I4 Southern blot hybridization studies with probes for VH25 1 and the J H locus showed that only 7 (10%) of the 68 monoclonal CLL cell populations had undergone Ig gene rearrangement involving vH5 genes. Two (3%) were found to have functionally rearranged vH5 genes that shared 298% sequence homology with 5-2R1, a VH25 1 gene isolated from a pre-B-cell acute lymphocytic leukemia. The other 5 CLL (7%) had functionally rearranged vH5 genes that each shared 299% nucleic acid sequence homology with a germline VH32 isolated from human sperm DNA. These data indicate that VH251 or VH32 also may be expressed by common CLL B cells with little or no somatic mutation. As such, these data conflict with those discussed above. Conceivably, the leukemia cells that express highly mutated Ig V genes may represent a unique subset of leukemias that differs from common CLL in ways other than just Ig V gene expression. Further work is necessary to determine whether there exist differences in the clinical and/or phenotypic characteristics of patients with leukemia cells that express mutated versus nonmutated Ig V genes. However, in general, CLL B cells that express highly mutated Ig V genes appear to be exceptional.
NORMAL CELL COUNTERPART TO THE CLL B CELL

CD5 B cells-"BI B cells." CLL B cells coexpress B-
cell-specific surface antigens and CD5 (Leu 1, OKTl).1'5-''8 As such, the normal counterpart to these leukemia cells arguably is the "CD5 B cell.""9 These cells constitute a small subpopulation of human B lymphocytes in the lymphoid organs and peripheral blood of normal adults that coexpress B-cell differentiation antigens and CD5 .120-'25 Such cells are enriched for B cells that spontaneously may produce IgM autoantibodies'26'128 and frequently may express autoantibody-associated C R I S . '~~, '~~, '~~ Recently, a new nomenclature has been adopted for CD5 B ~e1ls.l~' Because the CD5 surface antigen (1) may not be detected on the surface of B cells that otherwise have other developmental and/or phenotypic traits of "CD5 B cells,"'z5~'32-134 (2) may be induced on non-"CD5 B and (3) can be reduced on "CD5 B cells" by treatment with various c y t o k i n e~, '~~. '~~ it was argued that the term "CD5" (or "Ly-I") was not adequate for this type of B cell. Therefore, participants at the New York Academy of (Table 1) . However, the enzyme TdT apparently is active during the early human B-cell differentiation, resulting in human fetal Ig heavy chain gene rearrangements that have junctional N-sequence insertion^?^ As such, one cannot use the relative absence of N-sequence insertions to characterize Ig V genes that have rearranged during early human B-cell development. Also, human CD5 B cells coexpress higher levels of sIgD and CD23 than do their murine counterparts.1M Operationally then, expression of CD5 re- In fact, CD5 still may serve as a useful marker for identifying human B-1 B-cell malignancies. More than 90% of patients with B-cell CLL have leukemia cells that express CD5. Patients with leukemia B cells that do not express this surface differentiation antigen may have a distinct disease that differs from common CLL in its etiopathogenesis and/ or its expression of Ig genes. For example, we examined the Ig V genes expressed by the neoplastic cells of an unusual CLL patient that did not express CD5 but still secreted an IgM RF autoantibody. The nucleic acid sequence of the V, gene expressed by this CLL differed substantially (<96% homology) from that of any known germline V, gene.'58s159 Furthermore, nucleic acid sequence analyses of independent VH gene clones showed substantial intraclonal variation in the VH genes expressed by this leukemia cell population." Similar intraclonal diversity recently was observed in a case of small lymphocytic lymphoma (SLL) that also failed to express CD5," and in another CLL cell population that also was CD5-.'Io These findings contrast with those made in analyzing conventional CD5 B-cell CLL,89,92,93,106,'07.110 as discussed above. Collectively, these studies suggest that the expression of CD5 may help distinguish conventional "B-I B-cell" CLL from other types of B-cell leukemias that differ physiologically in the ways they process their expressed Ig V genes.
To evaluate for normal B cells that also may express Ig V genes similar to those often observed in B-cell CLL, investigators have examined lymphocytes in nonmalignant human lymphoid tissue for reactivity with MoAbs specific for autoantibody-associated Flow cytometric analyses of tonsillar lymphocytes from 19 subjects, for example, showed that the lymphocytes binding 17.109 are a subpopulation of Ig K-bearing B cells comprising 1.3% to 6.3% (mean = 3.9% f 1.2%) of the total lymphocytes, 3% to 16% (mean = 10% f 3%) ofthe K light chain-bearing cells, and from 46% to 97% (mean = 77% rf: 16%) of the cells expressing K light chains of the VJIb subgroup. G6-positive cells expressed either K or X light chains and comprised SO. 1% to 4.5% (mean = 2.2% f 1.2) ofthe total lymphocytes. Cells expressing both the 17.109 and G6 CRI comprised a very small subpopulation constituting less than 0.1% to I% (mean = 0.4% f 0.3%) of the total lymphocyte population.
Molecular studies indicate that such CRI-expressing tonsillar lymphocytes may express Ig V genes similar to that used by CRI-expressing CLL B cells. G6-reactive tonsillar lymphocytes, for example, are found to express 5 1 p 1 with little or no somatic m~tation."~ In fact, in more than 5,600 nucleotide bases of the Ig VH genes from 13 independent G6-reactive tonsillar B-cell clones, there were only three base differences detected. The absence of even nonconservative base changes indicates that the conserved Ig VH gene sequences are not the mere consequence of selection for cells having reactivity for the G6 MoAb. Rather, these data indicate that G6-reactive tonsillar B cells generally express homologous VHl genes that have not diversified through somatic mutation.
B cells that express such autoantibody-qswciated CRIs are confined to the mantle zones surrounding the germinal cenMantel zone B cells.
ters of secondary B-cell follicle^.^^^^^^ Tonsillar B cells can be delineated into subpopulations based on the differential expression of SI@, CD10, and receptors for peanut agglutinin (PNA). Mantle zone B cells bear SI@, but fail to bind PNA or MoAbs specific for CDlO (CALLA), whereas B cells within the germinal center generally lack sIgD, express low levels of CD10, and avidly bind PNA.'6L-163 Consistent with their mantle zone distribution, greater than 95% of CRI-positive B cells express sIgD but fail to bind PNA or MoAbs specific for CD 10.Lz5 Furthermore, multiparameter analyses indicate that human tonsillar B cells that express CD5 also have this phenotype, indicating that B-1 B cells may constitute a subpopulation of mantle zone 1ympho~ytes.l~~
It should be noted that sIgD-bearing cells constitute only 37% to 87% of the tonsillar B cells.L25 As such, the 17.109-reactive or G6-reactive cells, respectively, may constitute up to 17% or 12% of the mantle zone lymphocytes. These frequencies approach those noted for expression of these CRIs in B-cell CLL and argue that the Ig V gene repertoire of mantle zone B cells may be comparably restricted. Recent studies suggest that the expressed Ig VH gene repertoire of circulating B cells in adult peripheral blood also may be highly restricted. 164 It is conceivable then that transformation of lymphocytes such as those found in the mantle zone may account for the high frequency expression of autoantibodyassociated CRIs in CLL.
However, it seems that CLL B cells may originate from only a subset of such B cells. 
SOMATIC SELECTION OF CLL AUTOANTIBODIES
An important feature of the autoantibodies expressed in CLL is their "polyreactivity," or binding activity for two or more seemingly disparate self antigens. RF autoantibodies made by CLL B cells, for example, generally also are found to bind other "self' antigens, such as ssDNA, dsDNA, histones, cardiolipin, actin, thyroglobulin, and/or cytoskeletal c~m p o n e n t s .~-~J~~~'~~ Such polyreactivity is a feature also noted for antibodies produced during early B-cell development, even in animals raised in apparently germ-free environment~.~'"~*-'~' Th ese types of autoantibodies are not a priori pathogenic in that they can be detected in the sera of all individuals and appear physiologic. Because of this, several investigators have used the term "natural autoantibodies" to describe these types of antibodies.
Polyreactive IgM autoantibodies may be encoded by Ig V genes that are present in the germline DNA.'72 Accordingly, the frequent expression of polyreactive IgM autoantibodies in CLL may be a direct consequence of the frequent use of such Ig V genes, with little or no somatic mutation. As noted, a high proportion of CLL patients have leukemia cells expressing Ig V genes that encode CRIs frequently found to be associated with IgM autoantibodies, particularly RFs.84-86~90 Moreover, more than 90% of the monoclonal IgM paraproteins that bear both 17.109 and G6 CRIs are noted to have However, this model minimizes the contribution of the third complementarity determining region (CDR3) to the autoreactive binding activity of the Ig expressed in CLL. As discussed, this region of the Ig heavy chain is encoded by the D and JH gene segments that undergo recombination and Nterminal nucleic acid base insertion immediately before VH gene r e a~~a n g e m e n t .~~, '~~ Accordingly, the sequence of the CDR3 is generally idiosyncratic to each Ig VH gene rearrangement, as has been noted with all G6-positive heavy chains sequenced to date93r'25 (T. Johnson, S.F. Duffy, T.J. Kipps, unpublished observations). In view of the large potential for diversity in the CDR3 of G6-positive heavy chains,'25 the random pairing of a 17.109-positive K light chain with any G6-positive Ig heavy chain may not be anticipated to form an autoantibody if the CDR3 is critical to autoantibody-binding activity (Fig 2) .
To examine this, we generated murine transfectomas to pair the 17. expression vector that contains the functionally rearranged SMI VH1 gene flanked by unique restriction enzyme sites. This enabled us to exchange several different functional VHDJH exons of other G6-positive leukemia cells or tonsillar lymphocytes. Each of the rearranged VH genes within these genes shared more than 99% nucleic acid sequence homology to 5 1~1 , a VH1 gene expressed during early fetal development.93.94x'25 In contrast, these exons differed markedly in the CDR3. We found that the myeloma cells cotransfected with the original pair of Ig heavy and light chain genes of SMI secrete polyreactive IgM, RF a~toantibodies.'~~ However, myeloma cells cotransfected with the SMI K light chain gene and any I of 10 different G6-encoding VHDJH exons produced 17.109/G6-reactive IgM, that failed to have such autoantibody activity (Fig 2) . This indicates that such polyreactive binding activity of these natural autoantibodies is dependent on the somatically generated CDR3.
These results imply that the polyreactive binding activity of natural autoantibodies is a selected specificity. In human fetal spleen, B cells frequently express autoantibody-associated CRIs, such as G6 and 17. 109.174 Genetic mechanisms may enhance rearrangement of Ig V genes that encode CRIbearing IgM autoantibodies. IO3 However, random pairing of such Ig light and heavy chains only infrequently may give rise to polyreactive autoantibodies. Because more than 90% of Ig paraproteins that bear both CRIs have autoantibody activity, it appears that autoreactivity is a selected specificity.
In addition, several studies indicate that more than half of all CLL patients have leukemia cells that can be stimulated to secrete polyreactive aut~antibodies.~.~ This proportion greatly exceeds that noted for polyreactive B cells in normal embryonic tissues, cord blood, or adult peripheral blood. 
SYSTEMIC AUTOIMMUNE DISEASES ASSOCIATED WITH CLL
Patients with CLL frequently may develop intermittent autoimmune Soon after CLL popularly became recognized as a distinct clinical entity, investigators noted an association between CLL and various autoimmune diseases, such as AIHA'75,'78 and ITP.176 Less frequently, patientswith CLL are noted to have pure red blood cell aplasia18' or neutropenia7 secondary to a presumed autoimmunity against precursor cells in the bone marrow.
Larger retrospective surveys confirmed the association between certain types of autoimmune disorders and CLL. Duhrsen et alls3 studied the records of nearly 1,000 patients with either myeloproliferative or lymphoproliferative diseases for clinical manifestations of autoimmune pathology. Included in this survey were 104 patients with CLL. As a group, patients with CLL had the highest incidence of associated autoallergic hematologic diseases, accounting for more than 60% of all cases observed to have hemolytic anemia (9 of 14) or autoimmune thrombocytopenia (3 of 5). Similarly, Hamblin et a17 studied the prevalence of autoantibodies in 195 patients with B-cell CLL. Fifteen patients (7.7%) tested positive in the direct antiglobulin test for antierythrocyte autoantibodies. One of these 15 had high titer anti-I IgM, MoAbs produced by the leukemia cell clone. The other 14 had polyclonal IgG anti-red blood cell autoantibodies, 10 of which produced clinically detectable hemolytic anemia. Four patients (2.1%) had ITP, l patient (0.5%) had pure red blood cell aplasia, and 1 patient (0.5%) had isolated neutropenia thought to be secondary to antineutrophil autoantibodies. The incidence of autoantibodies increased later in more advanced stages of CLL. The incidences of such autoantibodies were significantly higher than in a similarly sized group of age-and sex-matched control subjects.
ORIGIN OF PATHOGENIC AUTOANTIBODIES IN CLL
Although pathogenic autoantibodies occasionally may be made by the clone of malignant B cells,'04,i60,188 generally such autoantibodies appear to be made by bystander B cells. Similar to studies on autoantibodies that arise in systemic autoimmune disease, one can discern autoantibodies with Ig K light chains or Ig X light chains in any one patient. Furthermore, Ig isotypes of such autoantibodies usually differ from that of the Ig expressed by the malignant B-cell clone. In addition, the circulating levels and the clinical significance of such autoantibodies do not relate directly to the duration or severity of the underlying lymphoproliferative disease. Moreover, immunosuppressive therapy may result in clinical remission of pathologic autoimmunity without affecting the overall leukemia cell burden. Collectively, these observations suggest that the cells producing pathogenic autoantibodies may originate from bystander B cells that are not related to the leukemic cell clone.
Although difficult to detect, especially in patients with high leukemia cell counts, such bystander B cells may be present in the peripheral blood of patients with CLL. We noted human antierythrocyte autoantibodies in mice with severe combined immunodeficiency (SCID) that were engrafted with peripheral blood leukocytes (PBL) from patients with CLL.'" SCID mice fail to develop functional T or B lymphocytes due to an autosomal, recessive Leukemia cells injected into the peritoneal cavity of these animals may survive for several weeks in vivo. Eight to 16 weeks after receiving PBL from patients with CLL, SCID mice develop human IgG autoantibodies to human red blood cells and/or high serum levels of human Ig. Soon thereafter, these animals develop lethal human B-cell tumors. In contrast to the original CLL cells, these human B-cell tumors are CDY, have genomic DNA of EBV, express antigens associated with latent EBV infection, and have distinctive Ig gene rearrangements by Southern. We conclude that bystander B cells, onginally present at 10.1% of the injected PBL, may generate tumors in CLL-reconstituted SCID mice that emulate the EBV-associated lymphoproliferations noted in SCID mice reconstituted with normal human PBL. '95-'97 Similar to the pathogenic autoantibodies that develop in patients with CLL, the human IgG antierythrocyte autoantibodies of such reconstituted mice apparently are produced by circulating bystander B cells that are not clonally related to the transferred CLL B-cell population. First, in addition to having different Ig isotypes, the antierythrocyte Ig may have Ig light chains that differ from that of the Ig expressed by the population of injected leukemia B cells. Second, although all mice received comparable numbers of PBL from patients with CLL, only a fraction of the mice developed antierythrocyte autoantibodies. Finally, the emergence of antierythrocyte autoantibodies in such SCID mice coincided with the development of high serum levels of human Ig. This invariably preceded the development of B-cell lymphomas that have clonal origins distinct from that of the original leukemia B-cell population. The data suggest that polyclonal activation and/or lymphoproliferation of bystander B cells may account for the antierythrocyte antibodies detected in these animals.
Conceivably, the occurrence of antierythrocyte or antiplatelet autoantibodies in CLL patients also may be associated with dysregulation of the cellular immune mechanisms that control latent EBV infections. Alternatively, the development of such autoantibodies may reflect a more generalized defect in the homeostatic mechanisms that prevent generation of antiself humoral immunity. According to this hypothesis, autoantibodies arise not from polyclonal B-cell activation, but rather from a pathologic immune response to self antigen.
Whatever hypothesis is advanced must take into consideration the peculiar predilection of CLL patients to develop autoantibodies primarily against hematologic cells (eg, erythrocytes, platelets, et^).^ This may reflect a requirement for the self antigen@) to be physically associated with or processed by either normal or leukemic B-1 B cells. Clearly, more studies are required to define the mechanism(s) that accounts for the oftentimes pathogenic autoantibodies that may arise in CLL. Such studies may contribute to our understanding of normal B-1 B cells and how they potentially may contribute to the maintenance of immunologic tolerance and/or to the development of systemic autoimmunity.
For
CONCLUSIONS
Common CLL is a B-I B-cell malignancy. The leukemia cells often make polyreactive autoantibodies and use a restricted repertoire of nonmutated Ig V genes. Recent studies indicate that somatic selection of B-1 B cells for polyspecific autoreactivity may play an important role in shaping the repertoire of Ig expressed by these cells. However, chronic stimulation of such long-lived B-l B cells by ubiquitous self antigens also may increase their risk for neoplastic transformation into CLL.
Even though CLL B cells often make autoantibodies, the Ig expressed by leukemia B cells generally do not contribute directly to the types of autoimmune diseases that frequently are observed in patients with this disease. CLL-associated autoimmune diseases generally result from the intermittent production of pathogenic autoantibodies that most commonly react with antigens present on human hematopoietic cells (eg, red blood cells or platelets). These autoantibodies are apparently produced by polyclonal bystander B cells as a consequence of an immune dysregulation associated with B-cell CLL.
The fact that CLL cells express a limited repertoire of Ig V genes that have not diversified substantially from the germline DNA implies that the surface Ig may be a convenient target antigen for passive or active immunotherapy. Current efforts to prepare additional anti-CRI MoAbs, to induce cytotoxic T lymphocytes reactive with idiotypic antigens on CLL cells, and to develop improved delivery systems for Igdirected immunotherapy may yield important advances in the treatment of this disease. 
